Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288046259> ?p ?o ?g. }
- W4288046259 endingPage "771" @default.
- W4288046259 startingPage "754" @default.
- W4288046259 abstract "Cannabinoid Receptor 2 (CB2) is a promising therapeutic target, particularly for inflammatory disorders and pain; however, clinical trials to date have been unsuccessful. Medicinal chemistry efforts have produced selective ligands with a wide range of core scaffolds. Optimisation for drug-like properties and oral administration has been demonstrated to be feasible, but few such compounds have been tested clinically to date. Recent crystal and cryo-EM structures are expected to facilitate rational ligand development and further optimisation. Although CB2 ligands can produce functional selectivity (bias) of signalling responses, few new classes of ligand have been studied in this context. The physiological relevance of CB2 signalling bias, and subcellular spatial organisation of CB2 signalling, remain to be elucidated. Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic potential. Promising preclinical data supports the applicability of CB2 activation in autoimmune and inflammatory diseases, pain, neurodegeneration, and osteoporosis. A diverse pharmacopoeia of cannabinoid ligands is available, which has led to considerable advancements in the understanding of CB2 function and extensive preclinical evaluation. However, until recently, most CB2 ligands were highly lipophilic and as such not optimal for clinical application due to unfavourable physicochemical properties. A number of strategies have been applied to develop CB2 ligands to achieve closer to ‘drug-like’ properties and a few such compounds have now undergone clinical trial. We review the current state of CB2 ligand development and progress in optimising physicochemical properties, understanding advanced molecular pharmacology such as functional selectivity, and clinical evaluation of CB2-targeting compounds. Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic potential. Promising preclinical data supports the applicability of CB2 activation in autoimmune and inflammatory diseases, pain, neurodegeneration, and osteoporosis. A diverse pharmacopoeia of cannabinoid ligands is available, which has led to considerable advancements in the understanding of CB2 function and extensive preclinical evaluation. However, until recently, most CB2 ligands were highly lipophilic and as such not optimal for clinical application due to unfavourable physicochemical properties. A number of strategies have been applied to develop CB2 ligands to achieve closer to ‘drug-like’ properties and a few such compounds have now undergone clinical trial. We review the current state of CB2 ligand development and progress in optimising physicochemical properties, understanding advanced molecular pharmacology such as functional selectivity, and clinical evaluation of CB2-targeting compounds. the strength of interaction between a ligand and receptor, typically quantified as the concentration of ligand that results in 50% of receptors binding ligand at equilibrium (Kd or Ki). A lesser concentration required to achieve 50% receptor binding indicates a higher affinity. Reported in this review via the parameter pKi. a receptor ligand that, upon interaction with a receptor, induces activation of one or more signalling pathways. a ligand that binds to a receptor elsewhere than the orthosteric binding site and, therefore, does not compete for binding with orthosteric ligands. By influencing receptor conformation, allosteric modulators may induce or restrict receptor activity alone or, more commonly, may positively or negatively influence the binding and/or activity of orthosteric ligands. a receptor ligand that binds to the orthosteric binding site (and can therefore compete for binding with other orthosteric ligands) but does not itself influence receptor activity. also known as biased agonism. The concept that a single receptor type can activate varying signalling patterns (may include different pathways or the same pathways to different degrees), depending on the specific ligand bound. This is produced via the stabilisation of different receptor conformations and, therefore, differential engagement with signalling effectors. a receptor ligand that reduces constitutive (non-ligand-induced) activity of a receptor by stabilising an inactive conformation. molecule that has affinity for a receptor. tendency to combine with or dissolve in nonpolar substances such as lipids. Can be measured via logD, logP. partition coefficient between aqueous and organic phases at a defined pH; a measure of lipophilicity. ‘c’ for calculated. partition coefficient between aqueous and organic phase of a neutral compound; a measure of lipophilicity. ‘c’ for calculated. the region in a receptor where the endogenous ligand binds. Orthosteric ligands also bind to (or have overlapping interactions with) this site/pocket and can compete for binding with endogenous ligand(s). a parameter for quantifying ligand affinity. The negative log concentration of ligand that results in 50% of receptors binding ligand at equilibrium. A larger pKi indicates higher affinity. For example, a pKi of 9 is equal to a Ki of 1 nM, or 10–9 M. A pKi of 6 is equal to a Ki of 1 μM, or 10–6 M. the relative propensity of a compound to interact with and/or produce activity via one effector (e.g., a receptor) as opposed to others. Represented in this review as the fold-difference in binding affinity between two effectors. For example, a CB2/CB1 selectivity of 1000 indicates that the concentration of ligand required to bind 50% of CB1 receptors is 1000 times greater than the same for CB2. the ability of a molecule to interact with its intended target. Encompasses molecular interactions with the target (e.g., affinity) and access to the target in vivo (e.g., drug distribution). in the context of GPCRs, refers to one type of molecular switch, where one or several amino acids play a key role in receptor activation by undergoing a conformational change and therefore mediating/driving the transition of the GPCR between conformations and/or stabilising a particular conformation. sum of surface areas of polar atoms in a molecule. Typically reported in Å2." @default.
- W4288046259 created "2022-07-27" @default.
- W4288046259 creator A5053915349 @default.
- W4288046259 creator A5058023236 @default.
- W4288046259 creator A5063807271 @default.
- W4288046259 creator A5073377306 @default.
- W4288046259 creator A5085208355 @default.
- W4288046259 date "2022-09-01" @default.
- W4288046259 modified "2023-10-01" @default.
- W4288046259 title "Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future" @default.
- W4288046259 cites W1530755879 @default.
- W4288046259 cites W1607650190 @default.
- W4288046259 cites W1965546476 @default.
- W4288046259 cites W1965682520 @default.
- W4288046259 cites W1982783897 @default.
- W4288046259 cites W1990190134 @default.
- W4288046259 cites W1992243124 @default.
- W4288046259 cites W1993908600 @default.
- W4288046259 cites W1998464082 @default.
- W4288046259 cites W2003063658 @default.
- W4288046259 cites W2010385221 @default.
- W4288046259 cites W2014493412 @default.
- W4288046259 cites W2027329965 @default.
- W4288046259 cites W2029298938 @default.
- W4288046259 cites W2041141578 @default.
- W4288046259 cites W2043406429 @default.
- W4288046259 cites W2044875852 @default.
- W4288046259 cites W2045665112 @default.
- W4288046259 cites W2054935554 @default.
- W4288046259 cites W2062413775 @default.
- W4288046259 cites W2069355282 @default.
- W4288046259 cites W2070171539 @default.
- W4288046259 cites W2071014521 @default.
- W4288046259 cites W2075213927 @default.
- W4288046259 cites W2076861026 @default.
- W4288046259 cites W2082237701 @default.
- W4288046259 cites W2086836468 @default.
- W4288046259 cites W2091459808 @default.
- W4288046259 cites W2091846235 @default.
- W4288046259 cites W2108437852 @default.
- W4288046259 cites W2114691708 @default.
- W4288046259 cites W2124879501 @default.
- W4288046259 cites W2133551580 @default.
- W4288046259 cites W2141671060 @default.
- W4288046259 cites W2157869010 @default.
- W4288046259 cites W2166554816 @default.
- W4288046259 cites W2312459263 @default.
- W4288046259 cites W2314299496 @default.
- W4288046259 cites W2399811012 @default.
- W4288046259 cites W2415744702 @default.
- W4288046259 cites W2431558107 @default.
- W4288046259 cites W2460083407 @default.
- W4288046259 cites W2548427983 @default.
- W4288046259 cites W2552622568 @default.
- W4288046259 cites W2566514911 @default.
- W4288046259 cites W2583642994 @default.
- W4288046259 cites W2588432550 @default.
- W4288046259 cites W2621218959 @default.
- W4288046259 cites W2725570536 @default.
- W4288046259 cites W2767612609 @default.
- W4288046259 cites W2769683875 @default.
- W4288046259 cites W2771298585 @default.
- W4288046259 cites W2775464734 @default.
- W4288046259 cites W2782232402 @default.
- W4288046259 cites W2787095923 @default.
- W4288046259 cites W2796419445 @default.
- W4288046259 cites W2886166021 @default.
- W4288046259 cites W2890490849 @default.
- W4288046259 cites W2896865935 @default.
- W4288046259 cites W2901738386 @default.
- W4288046259 cites W2912011779 @default.
- W4288046259 cites W2925168339 @default.
- W4288046259 cites W2928912053 @default.
- W4288046259 cites W2935826300 @default.
- W4288046259 cites W2939948833 @default.
- W4288046259 cites W2969724219 @default.
- W4288046259 cites W2973117472 @default.
- W4288046259 cites W2973624505 @default.
- W4288046259 cites W2977954157 @default.
- W4288046259 cites W3001018370 @default.
- W4288046259 cites W3003713259 @default.
- W4288046259 cites W3004133632 @default.
- W4288046259 cites W3004275505 @default.
- W4288046259 cites W3007438842 @default.
- W4288046259 cites W3012176060 @default.
- W4288046259 cites W3083832329 @default.
- W4288046259 cites W3121202849 @default.
- W4288046259 cites W3132495125 @default.
- W4288046259 cites W3155245897 @default.
- W4288046259 cites W3185421689 @default.
- W4288046259 cites W3209576972 @default.
- W4288046259 cites W4210571347 @default.
- W4288046259 cites W4212932996 @default.
- W4288046259 cites W4224219958 @default.
- W4288046259 cites W4242360498 @default.
- W4288046259 cites W4255022795 @default.
- W4288046259 doi "https://doi.org/10.1016/j.tips.2022.06.010" @default.
- W4288046259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35906103" @default.